Revance Therapeutics, Inc., a clinical stage biotechnology company based in Nashville, Tennessee, specializes in developing and commercializing novel botulinum toxin products for both aesthetic and therapeutic uses. The company, which went public in 2014, offers products like DAXXIFY for aesthetic improvements and is exploring its use in treating muscle movement disorders such as cervical dystonia and upper limb spasticity.
RVNC has been in the news recently: Crown Laboratories, Inc. plans to acquire Revance Therapeutics, Inc. for $6.66 per share, amounting to a total of $924 million, with the deal expected to finalize by the end of 2024. Additionally, Halper Sadeh LLC is investigating whether the sale is fair to Revance's shareholders.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
